Elizabeth Stern

Early life and background

Elizabeth Stern, later known in some sources as Elizabeth Stern Shankman, was born on 19 September 1915, in the silver-mining town of Cobalt, Ontario, Canada.[1][3][4][8] She was born into a Jewish family whose immigrant experience situated her within broader patterns of early twentieth‑century North American migration and minority life. Although detailed accounts of her parents and childhood are sparse in the surviving literature, biographical sources agree that she grew up at a time when both women and Jews faced structural discrimination in education and professional advancement, particularly in the sciences and medicine.[1][4]

Stern’s decision to pursue medical education was itself a barrier‑breaking step. In the 1930s, women comprised only a small minority of medical students in Canada and the United States. She enrolled at the University of Toronto, one of Canada’s leading research universities, where she undertook the rigorous course of study required for the medical degree. She received her medical degree (M.D.) in 1939, entering the profession just as the Second World War began.[1][3][4] This timing placed her at the cusp of major changes in medical research, including the post‑war expansion of cancer biology and epidemiology.

Education and advanced training

After completing her medical degree in 1939, Stern moved to the United States in 1940, a migration that would shape the rest of her career.[1][3][4] She pursued advanced training in pathology, the medical discipline concerned with the study of disease processes and tissue changes. Biographical profiles indicate that she undertook postgraduate training at the University of Pennsylvania School of Medicine, a leading institution for clinical and laboratory medicine.[1][3][4]

Stern also completed residencies at Cedars of Lebanon Hospital and Good Samaritan Hospital in Los Angeles, institutions that were building significant programs in clinical pathology in the mid‑twentieth century.[1][3][4][8] Through this training she became one of the earliest specialists in what would come to be known as cytopathology, the microscopic study of diseased cells. At a time when pathology was dominated by male physicians and heavily focused on tissue sections obtained at surgery or autopsy, Stern’s emphasis on exfoliative cytology—cells shed from the cervix and other sites—positioned her at the forefront of a new diagnostic approach.

In 1943, several years after her move to the United States, Stern became a naturalized U.S. citizen.[1][3][4] Her dual Canadian and American experience allowed her to participate fully in the rapidly expanding American biomedical research system that developed during and after the war.

Career beginnings and development

Following her residencies and board certification, Stern began her career in Los Angeles as director of laboratories and research at the Los Angeles Cancer Detection Center.[4][7][8] This role placed her directly in the emerging field of cancer screening at a time when public‑health agencies and clinicians were only beginning to explore systematic early detection programs. The Cancer Detection Center, part of a broader movement to create community‑based cancer clinics, offered Stern both a rich source of clinical material and an institutional base for long‑term observational studies.

Stern’s early work focused on refining the use of cervical smears—popularized through the Pap test developed by George Papanicolaou—for the early detection of cervical cancer.[1][4] Unlike many clinicians who used the Pap test primarily as a binary tool (normal vs. cancer), Stern was interested in the continuum of cellular changes from health to malignancy. She began to systematically classify abnormalities in cervical cells, proposing intermediate stages that would later align with the modern concept of cervical intraepithelial neoplasia.

Her clinical and laboratory work quickly attracted attention, and in the early 1960s she joined the faculty of the University of California, Los Angeles (UCLA). From 1963 she served as a professor in the School of Public Health, specializing in epidemiology, and by 1965 she had been promoted to full professor.[1][3] This appointment reflected both her scientific stature and the interdisciplinary nature of her work, which blended pathology, epidemiology, and public health.

Major scientific contributions

Pioneering work in cytopathology and cervical cancer progression

Stern is widely recognized as one of the first specialists in cytopathology, especially in the application of cellular analysis to cancer screening.[1][4][8] In her most cited work, she conducted large‑scale, longitudinal studies of cells collected from the cervix, seeking to map the process by which a normal epithelial cell becomes cancerous. Through careful classification of smear specimens, she identified approximately 250 distinct stages between normal cytology and advanced cervical cancer.[1][4]

This continuum model challenged more static views of cancer and provided empirical support for the idea that cervical cancer develops gradually over many years. By correlating cytologic features with clinical outcomes, Stern’s work helped establish that pre‑invasive lesions could be detected and treated before progression to invasive disease. Her findings contributed directly to the refinement of Pap smear screening protocols, including the interpretation of dysplasia and carcinoma in situ, and helped justify the implementation of regular screening programs for women in many countries.

First case report linking a virus to a specific cancer (1963)

One of Stern’s most historically significant achievements came in 1963, when she published what is regarded as the first case report linking a specific virus to a specific human cancer.[1] Working from her observations of cervical smears and clinical data, she reported a connection between herpes simplex virus (HSV) infection and cervical cancer. Although later research would nuance and, in some respects, revise the understanding of cervical carcinogenesis—especially with the identification of human papillomavirus (HPV) as the primary causal agent—Stern’s work was groundbreaking in several ways.

First, it provided concrete, case‑based evidence that chronic viral infection could be associated with malignancy, bolstering a then controversial idea that infectious agents might play a causal role in human cancers. Second, it demonstrated the power of combining cytologic surveillance with epidemiologic analysis to explore causal hypotheses. In the early 1960s, the notion of viral oncogenesis in humans remained speculative; Stern’s report helped move it toward mainstream scientific consideration.[1]

While subsequent research shifted the focus from herpes to HPV as the principal viral factor in cervical carcinogenesis, historians of medicine note Stern’s report as an important step in the broader recognition of viruses as potential oncogenic agents. Her work formed part of the intellectual background that made later discoveries about HPV and vaccines conceptually plausible.

Link between oral contraceptives and cervical cancer (1973)

In 1973, Stern published a landmark article in the journal Science that is credited as the first study to report a definite link between prolonged oral contraceptive use and cervical cancer.[1] Drawing on her expertise in epidemiology and her large databases of cytologic and clinical information, she analyzed the incidence of cervical dysplasia and cancer among women who had used oral contraceptives for extended periods.

Her findings suggested that long‑term use of the pill was associated with an increased risk of cervical cancer, particularly among women with other risk factors. At the time, oral contraceptives had been widely adopted for little more than a decade and were often promoted as a symbol of female autonomy without fully understood long‑term health consequences. Stern’s research introduced an important note of caution, emphasizing the need for ongoing surveillance and informed risk–benefit discussions.

The 1973 paper influenced clinical guidelines and public‑health debates by underscoring that hormonal contraceptives, like any medical intervention, could have complex effects on cancer risk. Subsequent research has both refined and, in some contexts, moderated assessments of the risk, but Stern’s work remains a key early example of rigorous, population‑based evaluation of women’s reproductive health technologies.[1]

Defining and classifying pre‑cancerous lesions

Beyond her named firsts, Stern played a crucial role in clarifying the nature and clinical significance of cervical dysplasia and carcinoma in situ. Through detailed morphologic criteria and long‑term follow‑up of patients, she helped define which cell changes were likely to regress, persist, or progress to invasive cancer.[1][3][4]

This work had practical implications for patient care. By distinguishing among grades of dysplasia, Stern contributed to the development of management strategies that could balance the risks of overtreatment against the dangers of progression. Her classifications anticipated later standardized systems for reporting cervical cytology and histology, such as the Bethesda system, which similarly emphasize the spectrum of intraepithelial lesions.

Awards, honors, and recognition

The biographical sources available emphasize Stern’s scientific contributions but provide relatively limited detail about specific awards and honors. Nonetheless, her promotion to full professor of epidemiology at UCLA by the mid‑1960s, a time when few women held senior academic posts in medical sciences, was itself a significant mark of recognition.[1][3]

Her pioneering status is reflected in later historical accounts that identify her as one of the first women to specialize in cytopathology and as a central figure in the development of cervical cancer screening. Articles assessing the history of women’s health research and of Pap smear programs frequently cite her work on the 250 stages of cervical carcinogenesis, the herpes–cervical cancer case report, and the oral contraceptive study as milestones.[1][3][4]

Contemporary retrospectives on women’s health and cancer prevention, including scientific and popular histories, now treat Stern as a key architect of modern approaches to cervical cancer prevention. For example, educational material from biomedical research institutions highlights her influence on public‑health initiatives and screening strategies aimed at reducing cervical cancer mortality.[3]

Personal life

Sources identify her married name as Elizabeth Stern Shankman, indicating that she married a man with the surname Shankman.[7][8] However, surviving biographical entries provide few details about the date of the marriage, her spouse’s background, or whether the couple had children. Her professional publications generally appear under the name Elizabeth Stern, reflecting common practice among women scientists of her generation to retain maiden names in their research identity.

The relative scarcity of personal details in the public record is itself indicative of the gendered structure of historical documentation in science. Male contemporaries often left extensive personal archives, whereas women’s personal narratives and correspondence were less frequently preserved or foregrounded. What can be inferred from the available sources is that Stern navigated a demanding career that spanned clinical service, laboratory research, teaching, and epidemiologic fieldwork at a time when support structures for women professionals were limited.

Legacy and historical impact

Elizabeth Stern’s legacy lies primarily in three interrelated domains: the conceptualization of cancer as a stepwise cellular process, the establishment of cytopathology as a diagnostic and epidemiologic tool, and the critical assessment of reproductive technologies in women’s health.

First, her demonstration of approximately 250 intermediate stages between normal cervical epithelium and advanced cancer provided a vivid empirical picture of carcinogenesis as a gradual, multi‑stage process rather than a sudden transformation.[1][4] This insight aligned with and reinforced emerging multistep models of cancer development across tissues. It also offered a powerful rationale for screening: if cancer evolves over years through recognizable pre‑cancerous changes, then carefully designed surveillance can catch disease early.

Second, Stern helped establish cytopathology as a field that bridged clinical practice and public health. By using large cohorts and long follow‑up, she showed that cytologic observations could be used not just for individual diagnosis but also for epidemiologic inference about risk factors and disease dynamics. This integrative approach became central to later screening programs for cervical cancer and other malignancies.

Third, her work on the relationship between oral contraceptives and cervical cancer risk exemplified an early, rigorous effort to evaluate the long‑term health effects of widely used reproductive technologies.[1] She approached the subject not from a moral or political standpoint but from careful analysis of data, foregrounding the importance of informed consent and risk awareness for women making decisions about contraception.

In historical perspective, Stern is now recognized as a pioneer in women’s health research. Later discussions of cervical cancer prevention—including the development of HPV screening, vaccination, and evolving Pap smear guidelines—build upon the foundational understanding she helped create. Her emphasis on stages of disease and on the interplay between infection, hormonal exposure, and cellular change anticipated much of the modern framework for thinking about cancer prevention.

Additionally, as a woman who rose to a full professorship in epidemiology at a major American university in the mid‑twentieth century, Stern contributed—by example—to the gradual normalization of women’s leadership in biomedical research and public health. Historical accounts of women in science often cite her career as illustrative of the possibilities and obstacles faced by female physicians of her generation.[1][3][4]

Later life and death

Stern continued her research and teaching at UCLA through the 1960s and 1970s, a period that saw increasing institutionalization of cancer registries, screening programs, and population‑based studies—developments to which her work substantially contributed.[1][3] Even as newer technologies and theories emerged, her frameworks for staging cervical cellular changes and for examining the role of infections and exogenous hormones remained influential.

On 18 August 1980, Stern died of cancer in Los Angeles, California.[1][8] She was 64 years old. Her death from the very disease category that she had spent her life studying adds a poignant note to her career. By 1980, however, cervical cancer screening programs inspired and informed by work like hers were already reducing mortality in many countries, a trend that would continue in subsequent decades.

In the years since her death, Stern’s contributions have been the subject of renewed attention from historians of medicine and advocates of women’s health. Encyclopedic entries, scientific retrospectives, and educational materials now routinely identify her as a central figure in the history of cervical cancer research and prevention.[1][3][4][8] Although her name is less widely known to the general public than those of some of her male contemporaries, within the field her legacy endures in everyday clinical practice wherever cervical cytology is used to detect early signs of cancer.